Back to mobile site

Greater Competition Does Not Impact Investment Thesis - Cantor Fitzgerald Reiterates Amarin Corporation (AMRN)at Overweight

June 22, 2022 5:44 PM EDT
Get Alerts AMRN Hot Sheet
Price: $1.13 +2.73%

Rating Summary:
    6 Buy, 12 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 6 | Down: 5 | New: 17
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $5.00 price target on Amarin Corporation (NASDAQ: AMRN).

The analyst comments: "We are lowering our estimates for U.S. Vascepa sales in 2022 and beyond. Generic competition for Vascepa is greater than we had initially anticipated. We are lowering our operating expenses in 2022 and beyond in the U.S. given AMRN's guidance on cost-cutting in the U.S. and re-allocation of resources to the international markets. These changes do not impact our positive investment thesis. Therefore, we are reiterating our 12-month OW rating and $5 PT for the stock."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $1.89 yesterday.

By Vlad Schepkov

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cantor Fitzgerald, Louise Chen, Vlad Schepkov